diphtheria, tetanus, acellular pertussis, Sabin inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine, adsorbed

This drug is an adsorbed pentavalent combination vaccine developed by Beijing Minhai Biotechnology (a subsidiary of Shenzhen Kangtai Biological Products). It is designed to protect infants and young children against five major infectious diseases: diphtheria, tetanus, pertussis (whooping cough), poliomyelitis (polio), and invasive infections caused by Haemophilus influenzae type b (Hib). The vaccine combines diphtheria toxoid, tetanus toxoid, acellular pertussis antigens (including pertussis toxoid, filamentous hemagglutinin, and pertactin), inactivated poliovirus types I, II, and III derived from Sabin strains (sIPV), and Haemophilus influenzae type b capsular polysaccharide conjugated to a carrier protein, adsorbed onto an aluminum hydroxide adjuvant. By utilizing Sabin strains for the inactivated polio component, the vaccine offers enhanced biosafety and lower manufacturing costs compared to traditional wild-type Salk strain-based vaccines. It is currently in Phase III clinical development in China.

Other names

DTaP-sIPV-Hib vaccineDTaP-sIPV/Hib vaccineDTacP-sIPV-Hib vaccineDTacP-sIPV/Hib vaccineHib-DTP-acellular poliovirus vaccine (Minhai Biological)Sabin strain-based DTaP-sIPV-Hib pentavalent vaccineSabin strain-based DTaP-sIPV/Hib pentavalent vaccineSabin strain-based DTacP-sIPV-Hib pentavalent vaccineSabin strain-based DTacP-sIPV/Hib pentavalent vaccine吸附无细胞百白破-脊髓灰质炎-b型流感嗜血杆菌联合疫苗吸附无细胞百白破灭活脊髓灰质炎和b型流感嗜血杆菌(结合)联合疫苗吸附无细胞百白破灭活脊髓灰质炎和b型流感嗜血杆菌联合疫苗